Molecular Targeted Therapy; Rheumatic Diseases/drug therapy; Rheumatic Diseases/immunology; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factors/metabolism; 4-1BB Ligand/antagonists & inhibitors; 4-1BB Ligand/metabolism; Animals; CD27 Ligand/antagonists & inhibitors; CD27 Ligand/metabolism; CD40 Ligand/antagonists & inhibitors; CD40 Ligand/metabolism; Cell Death; Cytokine TWEAK; Dendritic Cells/immunology; Fas Ligand Protein/antagonists & inhibitors; Fas Ligand Protein/metabolism; Humans; Immune Tolerance; Lymphocyte Activation; Lymphotoxin-alpha/antagonists & inhibitors; Lymphotoxin-alpha/metabolism; OX40 Ligand/antagonists & inhibitors; OX40 Ligand/metabolism; Signal Transduction; T-Lymphocytes/immunology; TNF-Related Apoptosis-Inducing Ligand/antagonists & inhibitors; TNF-Related Apoptosis-Inducing Ligand/metabolism; Tumor Necrosis Factor Ligand Superfamily Member 14/antagonists & inhibitors; Tumor Necrosis Factor Ligand Superfamily Member 14/metabolism; Tumor Necrosis Factor Ligand Superfamily Member 15/antagonists & inhibitors; Tumor Necrosis Factor Ligand Superfamily Member 15/metabolism; Tumor Necrosis Factors/immunology